Company intelligence / Profile preview

Redoxis

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Redoxis does not develop its own clinical-stage therapeutics but provides preclinical efficacy and mechanism-of-action evaluation services for drug candidates in autoimmune and inflammatory disease models. No proprietary clinical results; supports clients’ early-stage programs

Therapeutic areas: Immunology
Modalities: Small moleculeBiologicCell therapyGene therapymRNA-based drugs
Industry: Contract Research Organization

Partnerships

Collaborative projects with academic institutions such as Karolinska Institutetno major pharma partnerships publicly listed

Beyond the preview

Go deeper on Redoxis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Redoxis.

Explore the full profile